Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04884256 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
A Phase 2 study, sponsored by Cloudbreak Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT04884256 is a Phase 2 study that has completed, run by Cloudbreak Therapeutics. The registered enrollment target is 88 participants.
The verdict
NCT04884256, a Phase 2 study, has completed, sponsored by Cloudbreak Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications. Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye.
Interventions
- DRUG CBT-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04884256
The ClinicalTrials.gov registry entry for NCT04884256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cloudbreak Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBT-004 is the first listed.
NCT04884256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04884256 about?
NCT04884256 is a clinical study titled "Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula". STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators,...
What is the current status of trial NCT04884256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2023-12-21. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT04884256?
The interventions under investigation include: CBT-004 (DRUG).
Who is sponsoring clinical trial NCT04884256?
This trial is sponsored by Cloudbreak Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.